Current and emerging approaches to cochlear immunosuppression with translation to human inner ear stem cell therapy: A systematic review
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0318165 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, 2025. Verfasst von Nathan J Creber und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cambridge University Hospitals NHS Trust, United Kingdom. Hauptthemen laut MEDLINE: Stem Cell Transplantation, Ear, Inner, Immunosuppression Therapy, Cochlea. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Garnett Passe and Rodney Williams Memorial Foundation, NIHR Cambridge Biomedical Research Centre, Rinri Therapeutics Ltd.
Abstract (Originalsprache)
Hearing loss is a significant health burden across all stages of life. One in 5 people suffer hearing loss, with 5% of the world’s population experiencing disabling hearing loss. A large proportion of this loss is the consequence of damage or loss of neurosensory structures, termed “sensorineural” hearing loss. A recent advance in the treatment of sensorineural hearing loss has occurred, with the advent of inner ear stem cell therapy. Focus has pivoted from augmenting existing neural structures to regenerating neural frameworks. To date, stem cell therapy is limited by the host immune system and rejection of donor cells. A better understanding of immunity in the inner is ear required to progress stem cell therapy for hearing loss. This review outlines a contemporary understanding of the inner ear immune system. We discuss concepts of immune dysregulation that may lead to common inner ear pathologies, and, in doing so, review the efficacy of current pharmacotherapies that mitigate end organ damage through a process of immunosuppression. Current literature is appraised through a systematic review exploring two areas of focus; immunosuppression therapies for the treatment of inner ear pathology associated immune dysregulation, and, subsequently, the efficacy of immunosuppressive agents in translational models of inner ear stem cell therapy. Through greater understanding of these concepts, and systematic appraisal of the literature, this review summarises the literature for contemporary immunosuppressive regimes that may facilitate stem cell accommodation in the cochlea and auditory nerve.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cambridge University Hospitals NHS Trust, United Kingdom.
- Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney, Australia.
- University of Cambridge, United Kingdom.
ORCID-Profile: Nathan J Creber, Jameel Muzaffar, Matthew E Smith
Förderung
- Garnett Passe and Rodney Williams Memorial Foundation
- NIHR Cambridge Biomedical Research Centre
- Rinri Therapeutics Ltd
Zitieren
APA
Creber, N. J., Muzaffar, J., Gowrishankar, S., Borsetto, D., Phillips, V., & Smith, M. E. (2025). Current and emerging approaches to cochlear immunosuppression with translation to human inner ear stem cell therapy: A systematic review. PLOS ONE. https://doi.org/10.1371/journal.pone.0318165
Vancouver
Creber NJ, Muzaffar J, Gowrishankar S, Borsetto D, Phillips V, Smith ME. Current and emerging approaches to cochlear immunosuppression with translation to human inner ear stem cell therapy: A systematic review. PLOS ONE. 2025. doi:10.1371/journal.pone.0318165
BibTeX
@article{Creber2025,
author = {Creber, Nathan J and Muzaffar, Jameel and Gowrishankar, Shravan and Borsetto, Daniele and Phillips, Veronica and Smith, Matthew E},
title = {Current and emerging approaches to cochlear immunosuppression with translation to human inner ear stem cell therapy: A systematic review},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0318165}
}
EUVIMED